GlaxoSmithKline PLC (GSK): Today's Featured Drugs Winner

GlaxoSmithKline ( GSK) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.6%. By the end of trading, GlaxoSmithKline rose 60 cents (1.3%) to $46.04 on average volume. Throughout the day, 1.9 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.3 million shares. The stock ranged in a price between $45.47-$46.07 after having opened the day at $45.50 as compared to the previous trading day's close of $45.44. Other companies within the Drugs industry that increased today were: Somaxon Pharmaceuticals ( SOMX), up 61.5%, Supernus Pharmaceuticals ( SUPN), up 37%, ADVENTRX Pharmaceuticals ( ANX), up 19.1%, and Cormedix ( CRMD), up 17.3%.

GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $113.61 billion and is part of the health care sector. The company has a P/E ratio of 13.6, below the average drugs industry P/E ratio of 14.3 and below the S&P 500 P/E ratio of 17.7. Shares are down 1.4% year to date as of the close of trading on Tuesday. Currently there are six analysts that rate GlaxoSmithKline a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Natural Alternatives International ( NAII), down 18.4%, StemCells ( STEM), down 17.2%, Anthera Pharmaceuticals ( ANTH), down 16.9%, and MEI Pharma ( MEIP), down 12.8%, were all losers within the drugs industry with Onyx Pharmaceuticals ( ONXX) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

European, Wall Street Futures Slip; Dollar Dips as Trump Hits China on Trade

European, Wall Street Futures Slip; Dollar Dips as Trump Hits China on Trade